What Next for Keryx Biopharmaceuticals (KERX) Stock After Today’s Big Increase?

September 17, 2017 - By Ellis Scott

Investors sentiment increased to 1.22 in Q4 2016. Its up 0.15, from 1.07 in 2016Q3. It is positive, as 9 investors sold Keryx Biopharmaceuticals shares while 32 reduced holdings. 19 funds opened positions while 31 raised stakes. 65.62 million shares or 1.53% more from 64.63 million shares in 2016Q3 were reported.
Kcg Holdg invested in 0% or 23,870 shares. Creative Planning invested 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX). Ubs Asset Management Americas holds 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX) for 38,214 shares. Great West Life Assurance Co Can holds 0% or 10,000 shares. Blackrock Institutional Na has 2.62 million shares. Schwab Charles Inv Mgmt Incorporated invested 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX). Blackrock Fund Advsrs holds 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX) for 2.37M shares. Alliancebernstein Lp, New York-based fund reported 149,340 shares. Millennium Mgmt Limited Liability Corp holds 0.01% or 857,234 shares. State Board Of Administration Of Florida Retirement System stated it has 0% in Keryx Biopharmaceuticals (NASDAQ:KERX). Rhumbline Advisers invested in 0% or 92,626 shares. Ny State Common Retirement Fund reported 140,577 shares. Moreover, Prudential Inc has 0% invested in Keryx Biopharmaceuticals (NASDAQ:KERX) for 10,095 shares. Fmr Limited Liability has invested 0% in Keryx Biopharmaceuticals (NASDAQ:KERX). Point72 Asia (Hong Kong) has invested 0% in Keryx Biopharmaceuticals (NASDAQ:KERX).

Since April 5, 2017, it had 0 insider purchases, and 6 insider sales for $59,425 activity. 1,441 shares valued at $8,603 were sold by Neylan John F. on Monday, May 1. Adams Brian had sold 642 shares worth $3,724. Holmes Scott A also sold $8,603 worth of Keryx Biopharmaceuticals (NASDAQ:KERX) shares. Madison Greg also sold $24,608 worth of Keryx Biopharmaceuticals (NASDAQ:KERX) on Monday, May 1.

The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) is a huge mover today! The stock increased 5.89% or $0.4 on September 15, reaching $7.19. About 3.03M shares traded or 197.06% up from the average. Keryx Biopharmaceuticals (NASDAQ:KERX) has risen 13.56% since September 17, 2016 and is uptrending. It has underperformed by 3.14% the S&P500.
The move comes after 5 months positive chart setup for the $853.81M company. It was reported on Sep, 17 by Barchart.com. We have $7.77 PT which if reached, will make NASDAQ:KERX worth $68.30M more.

Wall Street await Keryx Biopharmaceuticals (NASDAQ:KERX) to release earnings on November, 8. Analysts forecast earnings per share of $-0.17, up exactly $0.22 or 56.41 % from 2014’s $-0.39 EPS. After posting $-0.21 EPS for the previous quarter, Keryx Biopharmaceuticals’s analysts now forecast -19.05 % EPS growth.

Keryx Biopharmaceuticals (NASDAQ:KERX) Ratings Coverage

Among 15 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 have Buy rating, 2 Sell and 7 Hold. Therefore 40% are positive. Keryx Biopharmaceuticals had 35 analyst reports since July 23, 2015 according to SRatingsIntel. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) has “Market Outperform” rating given on Wednesday, March 9 by JMP Securities. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) earned “Buy” rating by Maxim Group on Tuesday, March 29. The company was upgraded on Friday, February 26 by Raymond James. Citigroup initiated Keryx Biopharmaceuticals (NASDAQ:KERX) on Thursday, September 3 with “Sell” rating. The firm has “Equal-Weight” rating given on Tuesday, July 25 by Morgan Stanley. On Tuesday, August 2 the stock rating was downgraded by FBR Capital to “Market Perform”. The stock has “Hold” rating by Brean Capital on Tuesday, August 2. The rating was maintained by Maxim Group with “Buy” on Thursday, July 20. The firm earned “Equal-Weight” rating on Monday, October 5 by Morgan Stanley. TH Capital downgraded Keryx Biopharmaceuticals (NASDAQ:KERX) rating on Monday, August 10. TH Capital has “Buy” rating and $6.0 target.

More notable recent Keryx Biopharmaceuticals (NASDAQ:KERX) news were published by: Globenewswire.com which released: “Keryx Biopharmaceuticals Announces Second Quarter 2017 Financial Results and …” on July 27, 2017, also Seekingalpha.com with their article: “Keryx’s Path To Profitability Seems Clearer Now” published on June 13, 2017, Fool.com published: “Why Keryx Biopharmaceuticals Stock Soared 11.6% Higher in June” on July 08, 2017. More interesting news about Keryx Biopharmaceuticals (NASDAQ:KERX) were released by: Globenewswire.com and their article: “Keryx Biopharmaceuticals to Webcast its Presentations at Investor Healthcare …” published on September 05, 2017 as well as Seekingalpha.com‘s news article titled: “Captain Keryx Beams Up Sales” with publication date: August 08, 2017.

Keryx Biopharmaceuticals, Inc. is a biopharmaceutical firm focused on the development of medicines for people with renal disease. The company has market cap of $853.81 million. The Firm is engaged in the manufacture, development and commercialization of products for use in treating human diseases. It currently has negative earnings. The Company’s marketed product, Auryxia , which is an orally available, absorbable, iron medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: